Patents by Inventor Marianne Kjalke

Marianne Kjalke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII Molecules with Reduced VWF Binding
    Publication number: 20170020992
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Gert Bolt, Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen, Magali Zundel
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20160318991
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Stabilized Factor VIII Variants
    Publication number: 20160264645
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 15, 2016
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke
  • Pharmaceutical Composition Suitable for Treatment of Haemophilia
    Publication number: 20160120954
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 5, 2016
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20160002314
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 7, 2016
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII Molecules With Reduced VWF Binding
    Publication number: 20150376262
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 31, 2015
    Inventors: Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Olsen, Jens Jacob Hansen
  • Compounds suitable for treatment of haemophilia
    Patent number: 9125890
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 8, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20150080309
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens J. Hansen
  • Pharmaceutical Composition Suitable for Treatment of Haemophilia
    Publication number: 20150045303
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 12, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA
    Publication number: 20140018297
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 16, 2014
    Inventors: Gert Bolt, Ditte Marie Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • STABILIZED FACTOR VIII VARIANTS
    Publication number: 20130183280
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: July 6, 2011
    Publication date: July 18, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke
  • Factor VIII Molecules With Reduced VWF Binding
    Publication number: 20130040888
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: February 2, 2011
    Publication date: February 14, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen
  • FXIII Variants with Improved Properties
    Publication number: 20090130086
    Abstract: The present invention concerns variant factor XIII, wherein the rate of activation of said variant by thrombin is faster than for wild type FXIII. Methods for enhancing fibrin clot formation, pharmaceutical compositions and the use for the manufacture of medicaments wherein the variant factor XIII is applied are disclosed.
    Type: Application
    Filed: February 27, 2006
    Publication date: May 21, 2009
    Applicant: Novo Nordisk Health Care AG
    Inventors: Rasmus Roejkjaer, Asser Sloth Andersen, Marianne Kjalke, Ole Hvilsted Olsen, Henning Ralf Stennicke
  • Dimeric TF antagonists
    Publication number: 20060160741
    Abstract: Dimer FVII polypeptides, which binds and inhibits two TF molecules simultaneously.
    Type: Application
    Filed: March 27, 2006
    Publication date: July 20, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Marianne Kjalke, Palle Jakobsen, Henning Stennicke
  • Pharmaceutical composition comprising factor VIIa and anti-TFPI
    Patent number: 7015194
    Abstract: The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: March 21, 2006
    Assignee: Novo Nordisk A/S
    Inventor: Marianne Kjalke
  • Human tissue factor antibodies
    Publication number: 20050169927
    Abstract: The present invention relates to isolated fully human antibodies that immunoreacts with human tissue factor (TF) to inhibit the binding of coagulation factor VIIa (FVIIa).
    Type: Application
    Filed: March 31, 2005
    Publication date: August 4, 2005
    Applicant: Novo Nordisk A/S
    Inventors: Per-Ola Freskgaard, Jes Clausen, Brit Sorensen, Marianne Kjalke
  • Human tissue factor antibodies
    Publication number: 20040001830
    Abstract: The present invention relates to isolated fully human antibodies that immunoreacts with human tissue factor (TF) to inhibit the binding of coagulation factor VIIa (FVIIa).
    Type: Application
    Filed: September 30, 2002
    Publication date: January 1, 2004
    Inventors: Per-Ola Freskgaard, Jes Clausen Clausen, Brit Binow Sorensen, Marianne Kjalke
  • Dimeric TF antagonist
    Publication number: 20030229018
    Abstract: Dimer FVII polypeptides, which binds and inhibits two TF molecules simultaneously.
    Type: Application
    Filed: March 12, 2003
    Publication date: December 11, 2003
    Inventors: Marianne Kjalke, Palle Jakobsen, Henning Ralf Stennicke
  • Pharmaceutical composition comprising factor VIIa and anti-TFPI
    Publication number: 20030073638
    Abstract: The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.
    Type: Application
    Filed: October 16, 2002
    Publication date: April 17, 2003
    Inventor: Marianne Kjalke